Menu Search
Equities

YiChang HEC ChangJiang Pharmaceutical Co Ltd

1558:HKG.HS

YiChang HEC ChangJiang Pharmaceutical Co Ltd

Actions
  • Price (HKD)13.06
  • Today's Change0.10 / 0.77%
  • Shares traded1.01m
  • 1 Year change+82.91%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.

  • Revenue in HKD (TTM)6.80bn
  • Net income in HKD2.15bn
  • Incorporated2001
  • Employees4.62k
  • Location
    YiChang HEC ChangJiang Pharmaceutical Co LtdNo. 38, Binjiang Road, Yidu CityDONGGUAN 443300ChinaCHN
  • Phone+86 76 981768866
  • Fax+86 76 981768866
  • Websitehttp://www.hec-changjiang.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		1558:HKG since
announced		Transaction
value
Dongguan Hec Taigen Biopharmaceuticals Co LtdAnnounced22 Nov 202322 Nov 2023Announced55.11%4.98m
Data delayed at least 15 minutes, as of May 02 2024 09:08 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.